JPWO2020069068A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020069068A5 JPWO2020069068A5 JP2021516916A JP2021516916A JPWO2020069068A5 JP WO2020069068 A5 JPWO2020069068 A5 JP WO2020069068A5 JP 2021516916 A JP2021516916 A JP 2021516916A JP 2021516916 A JP2021516916 A JP 2021516916A JP WO2020069068 A5 JPWO2020069068 A5 JP WO2020069068A5
- Authority
- JP
- Japan
- Prior art keywords
- solid form
- peaks
- theta
- degrees
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007787 solid Substances 0.000 claims description 104
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 28
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 16
- 230000009529 traumatic brain injury Effects 0.000 claims description 16
- 230000006735 deficit Effects 0.000 claims description 15
- 208000002193 Pain Diseases 0.000 claims description 13
- 208000029028 brain injury Diseases 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000027418 Wounds and injury Diseases 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 10
- 208000014674 injury Diseases 0.000 claims description 10
- 229940126062 Compound A Drugs 0.000 claims description 9
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 9
- 208000023105 Huntington disease Diseases 0.000 claims description 9
- 208000010125 myocardial infarction Diseases 0.000 claims description 9
- 208000031225 myocardial ischemia Diseases 0.000 claims description 9
- 230000000626 neurodegenerative effect Effects 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 206010011878 Deafness Diseases 0.000 claims description 7
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 210000003169 central nervous system Anatomy 0.000 claims description 7
- 208000016354 hearing loss disease Diseases 0.000 claims description 7
- 206010027599 migraine Diseases 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 7
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims description 6
- 208000012886 Vertigo Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 208000017004 dementia pugilistica Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 238000011275 oncology therapy Methods 0.000 claims description 6
- 231100000889 vertigo Toxicity 0.000 claims description 6
- 230000003542 behavioural effect Effects 0.000 claims description 5
- 208000019622 heart disease Diseases 0.000 claims description 5
- 206010000117 Abnormal behaviour Diseases 0.000 claims description 4
- 208000000044 Amnesia Diseases 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- 208000019505 Deglutition disease Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 206010012335 Dependence Diseases 0.000 claims description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 4
- 206010013774 Dry eye Diseases 0.000 claims description 4
- 206010013887 Dysarthria Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 206010065390 Inflammatory pain Diseases 0.000 claims description 4
- 208000026139 Memory disease Diseases 0.000 claims description 4
- 206010044565 Tremor Diseases 0.000 claims description 4
- 208000005298 acute pain Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 208000004209 confusion Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 230000010370 hearing loss Effects 0.000 claims description 4
- 231100000888 hearing loss Toxicity 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 230000006984 memory degeneration Effects 0.000 claims description 4
- 208000023060 memory loss Diseases 0.000 claims description 4
- 230000036651 mood Effects 0.000 claims description 4
- 230000004973 motor coordination Effects 0.000 claims description 4
- 208000004296 neuralgia Diseases 0.000 claims description 4
- 208000021722 neuropathic pain Diseases 0.000 claims description 4
- 230000004112 neuroprotection Effects 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 206010010254 Concussion Diseases 0.000 claims description 3
- 206010017943 Gastrointestinal conditions Diseases 0.000 claims description 3
- 206010042458 Suicidal ideation Diseases 0.000 claims description 3
- 208000009205 Tinnitus Diseases 0.000 claims description 3
- 230000005856 abnormality Effects 0.000 claims description 3
- 230000005961 cardioprotection Effects 0.000 claims description 3
- 230000007278 cognition impairment Effects 0.000 claims description 3
- 230000009514 concussion Effects 0.000 claims description 3
- 231100000895 deafness Toxicity 0.000 claims description 3
- 208000032625 disorder of ear Diseases 0.000 claims description 3
- 210000005003 heart tissue Anatomy 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 230000008929 regeneration Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 231100000886 tinnitus Toxicity 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 claims description 3
- 230000000007 visual effect Effects 0.000 claims description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 208000002720 Malnutrition Diseases 0.000 claims description 2
- 208000027530 Meniere disease Diseases 0.000 claims description 2
- 206010029240 Neuritis Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 206010030043 Ocular hypertension Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000005457 endolymphatic hydrops Diseases 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 208000016361 genetic disease Diseases 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 230000009610 hypersensitivity Effects 0.000 claims description 2
- 230000001071 malnutrition Effects 0.000 claims description 2
- 235000000824 malnutrition Nutrition 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 claims 11
- 238000001157 Fourier transform infrared spectrum Methods 0.000 claims 3
- 238000005079 FT-Raman Methods 0.000 claims 2
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 41
- 238000000034 method Methods 0.000 description 37
- 208000006011 Stroke Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 6
- 208000032109 Transient ischaemic attack Diseases 0.000 description 4
- 201000010875 transient cerebral ischemia Diseases 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 206010014665 endocarditis Diseases 0.000 description 2
- 208000015210 hypertensive heart disease Diseases 0.000 description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 2
- 208000001286 intracranial vasospasm Diseases 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 208000008494 pericarditis Diseases 0.000 description 2
- 208000004124 rheumatic heart disease Diseases 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 208000013883 Blast injury Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000001593 cAMP accumulation Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 206010013395 disorientation Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024104074A JP2024114885A (ja) | 2018-09-26 | 2024-06-27 | 多形化合物およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736979P | 2018-09-26 | 2018-09-26 | |
| US62/736,979 | 2018-09-26 | ||
| PCT/US2019/053076 WO2020069068A1 (en) | 2018-09-26 | 2019-09-26 | Polymorphic compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024104074A Division JP2024114885A (ja) | 2018-09-26 | 2024-06-27 | 多形化合物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502405A JP2022502405A (ja) | 2022-01-11 |
| JP2022502405A5 JP2022502405A5 (https=) | 2022-10-04 |
| JPWO2020069068A5 true JPWO2020069068A5 (https=) | 2022-10-04 |
Family
ID=69885558
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516916A Pending JP2022502405A (ja) | 2018-09-26 | 2019-09-26 | 多形化合物およびその使用 |
| JP2024104074A Pending JP2024114885A (ja) | 2018-09-26 | 2024-06-27 | 多形化合物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024104074A Pending JP2024114885A (ja) | 2018-09-26 | 2024-06-27 | 多形化合物およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10765693B2 (https=) |
| EP (1) | EP3856741A4 (https=) |
| JP (2) | JP2022502405A (https=) |
| KR (1) | KR20210093864A (https=) |
| CN (1) | CN112930349A (https=) |
| AU (1) | AU2019346585B2 (https=) |
| BR (1) | BR112021005290A2 (https=) |
| CA (1) | CA3113250A1 (https=) |
| EA (1) | EA202190576A1 (https=) |
| IL (1) | IL281718A (https=) |
| MX (1) | MX2021003515A (https=) |
| WO (1) | WO2020069068A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102445887B1 (ko) | 2016-04-21 | 2022-09-21 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법 |
| IL276358B2 (en) | 2018-02-09 | 2024-11-01 | Astrocyte Pharmaceuticals Inc | Compounds and methods for treating addiction and related disorders |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| MX2023014655A (es) | 2021-07-12 | 2024-01-12 | Acadia Pharm Inc | Formas cristalinas de trofinetida. |
| WO2023091791A1 (en) * | 2021-11-22 | 2023-05-25 | Astrocyte Pharmaceuticals, Inc. | Methods of treating neurological and cardiovascular conditions |
| WO2024097387A1 (en) * | 2022-11-03 | 2024-05-10 | Astrocyte Pharmaceuticals, Inc. | Compositions for intravenous administration |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69428536T2 (de) | 1993-07-13 | 2002-06-06 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A3 -adenosin -rezeptor agonisten |
| US7348315B2 (en) | 1995-03-23 | 2008-03-25 | The University Of Connecticut | Methods of treating heart failure with modified ATP, ADP and AMP compounds |
| IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| US6586413B2 (en) | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| WO2001051919A2 (en) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| US7087589B2 (en) * | 2000-01-14 | 2006-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methanocarba cycloakyl nucleoside analogues |
| JP4012070B2 (ja) | 2001-01-16 | 2007-11-21 | カン−フィテ・バイオファーマ・リミテッド | ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用 |
| US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| US7557092B2 (en) | 2002-11-21 | 2009-07-07 | University Of Utah Research Foundation | Purinergic modulation of smell |
| GB0405009D0 (en) * | 2004-03-05 | 2004-04-07 | Cambridge Biotechnology Ltd | Analgesics |
| JP2008512457A (ja) | 2004-09-09 | 2008-04-24 | アメリカ合衆国 | Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体 |
| WO2006091905A1 (en) | 2005-02-25 | 2006-08-31 | Gilead Sciences, Inc. | Bicyclo (3.1.0) hexane derivatives as antiviral compounds |
| WO2007020018A1 (en) | 2005-08-12 | 2007-02-22 | Universite Libre De Bruxelles | Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies |
| WO2007139775A2 (en) | 2006-05-23 | 2007-12-06 | University Of Connecticut | N-methanocarba derivatives to treat cardiac diseases |
| WO2008021552A2 (en) | 2006-08-18 | 2008-02-21 | Duke University | Biased ligands and methods of identifying same |
| US7867983B2 (en) | 2007-03-29 | 2011-01-11 | The University Of Connecticut | Methods to protect skeletal muscle against injury |
| JP5592262B2 (ja) | 2007-10-15 | 2014-09-17 | キャン−ファイト・バイオファーマ・リミテッド | 肝細胞の増殖を誘導する方法及びその使用 |
| US20100256086A1 (en) | 2007-11-23 | 2010-10-07 | Bar-Ilan Univetrsity | Non-hydrolyzable nucleoside di- or tri-phosphate derivatives and uses thereof |
| CA2720037C (en) | 2008-03-31 | 2016-08-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as a3 adenosine receptor-selective agonists |
| WO2010014921A2 (en) | 2008-08-01 | 2010-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists and partial agonists |
| US8916570B2 (en) | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
| KR20130097813A (ko) | 2008-04-21 | 2013-09-03 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
| US8399018B2 (en) | 2008-07-21 | 2013-03-19 | Otonomy, Inc. | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
| US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
| EP2429565A4 (en) | 2009-04-15 | 2012-11-14 | Univ California | NEURONIC OR NERVE PEPTIDES AND APTAMERS |
| WO2011068978A1 (en) | 2009-12-02 | 2011-06-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methanocarba adenosine derivatives and dendrimer conjugates thereof |
| WO2011077435A1 (en) | 2009-12-22 | 2011-06-30 | Bar-Ilan University | Compositions and methods for reducing intraocular pressure |
| ES2654363T3 (es) | 2010-02-22 | 2018-02-13 | University Of Connecticut | Derivados de AMP para tratar enfermedades cardíacas |
| US8691775B2 (en) | 2010-04-19 | 2014-04-08 | Back Bay Scientific, Llc | Use of drugs that activate P2Y receptors to enhance synaptogenesis |
| US9132131B2 (en) | 2011-04-21 | 2015-09-15 | Saint Louis University | Use of adenosine A3 receptor agonists for treatment of neuropathic pain |
| US20140241990A1 (en) | 2011-09-30 | 2014-08-28 | Tufts University | Methods of using adenosine a1 receptor activation for treating depression |
| EA034135B9 (ru) | 2013-03-13 | 2020-04-10 | Тафтс Юниверсити | Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов |
| WO2015080940A1 (en) | 2013-11-27 | 2015-06-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists |
| EP3253388A4 (en) | 2015-02-04 | 2018-11-21 | Baker Heart and Diabetes Institute | A method of treatment and compounds for use therein |
| KR102445887B1 (ko) | 2016-04-21 | 2022-09-21 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법 |
| IL276358B2 (en) * | 2018-02-09 | 2024-11-01 | Astrocyte Pharmaceuticals Inc | Compounds and methods for treating addiction and related disorders |
-
2019
- 2019-09-26 EA EA202190576A patent/EA202190576A1/ru unknown
- 2019-09-26 US US16/583,570 patent/US10765693B2/en active Active
- 2019-09-26 EP EP19867559.7A patent/EP3856741A4/en active Pending
- 2019-09-26 MX MX2021003515A patent/MX2021003515A/es unknown
- 2019-09-26 CA CA3113250A patent/CA3113250A1/en active Pending
- 2019-09-26 AU AU2019346585A patent/AU2019346585B2/en active Active
- 2019-09-26 CN CN201980071019.6A patent/CN112930349A/zh active Pending
- 2019-09-26 BR BR112021005290-9A patent/BR112021005290A2/pt unknown
- 2019-09-26 WO PCT/US2019/053076 patent/WO2020069068A1/en not_active Ceased
- 2019-09-26 KR KR1020217012486A patent/KR20210093864A/ko not_active Ceased
- 2019-09-26 JP JP2021516916A patent/JP2022502405A/ja active Pending
-
2020
- 2020-07-28 US US16/940,451 patent/US11324769B2/en active Active
-
2021
- 2021-03-22 IL IL281718A patent/IL281718A/en unknown
-
2024
- 2024-06-27 JP JP2024104074A patent/JP2024114885A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022502405A5 (https=) | ||
| JP2022088642A5 (https=) | ||
| JP2009509921A5 (https=) | ||
| KR101799005B1 (ko) | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
| JP6215971B2 (ja) | てんかん又はてんかん−関連症侯群の予防又は治療用フェニルアルキルカルバメート化合物｛ｐｈｅｎｙｌａｌｋｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｅｐｉｌｅｐｓｙｏｒｅｐｉｌｅｐｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅ｝ | |
| JPWO2020069068A5 (https=) | ||
| AU2022201709B2 (en) | Mono-(acid) salts of 6-aminoisoquinolines and uses thereof | |
| JP6574756B2 (ja) | Ｂａｃｅ１阻害剤 | |
| JP2006502143A (ja) | 向代謝型グルタミン酸受容体のアセトフェノン増強因子 | |
| FI3494119T3 (fi) | Yhdisteitä ja koostumuksia ja niiden käyttötapoja | |
| JP2021528427A5 (https=) | ||
| JP2005502616A5 (https=) | ||
| CN107406420A (zh) | 取代的三唑及与其相关的方法 | |
| KR102854594B1 (ko) | 신규한 화합물 | |
| AU2005302608A1 (en) | Pyrimidine and quinoline potentiators of metabotropic glutamate receptors | |
| JP2016506939A5 (https=) | ||
| JP2001503387A (ja) | Ｎｋ１およびｎｋ２アンタゴニストとしてのアシルアミノアルケニレン―アミド誘導体 | |
| AU2026200097A1 (en) | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof | |
| NL1028664C2 (nl) | Sulfonamideverbindingen voor de behandeling van neurodegeneratieve ziekten. | |
| JPWO2023139534A5 (https=) | ||
| JP2003532714A (ja) | ５−ｈｔ７レセプターアンタゴニスト | |
| JP2016513677A5 (https=) | ||
| NZ774215A (en) | Polymorphic compounds and uses thereof | |
| JPWO2020249796A5 (https=) | ||
| JP2011506391A (ja) | カリウムチャネル活性化因子として有用な、新規の２−エチル−メチル−アミノ−３−アミド−６−アミノ−ピリジン誘導体 |